Abbott India

₹26,345As of Sun 8 Nov 2026, 12:00 UTC
NSE:ABBOTINDIAHealthcare
Country India
PE (Fwd) 31.47
TSR 10Y CAGR 19.62%
Div yield 1.99%
ROE —
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.07
PE TTM 36.07
TSR TTM (7.01%)
Mkt cap ₹555.1B
ROIC —
SE Grade™
Value
Quality
Moat
1Y Price
Reference
₹28,207
7.07%
(70.12%)
Price above Reference Value
FY23
FY24
FY25
FY26
Earnings per share₹
446.80
565.30
665.64
730.39
18.87%
26.52%
17.75%
9.73%
Revenue₹B
53.49
58.49
64.09
69.29
8.86%
9.35%
9.58%
8.11%
TTM
FYE 31 Mar INR
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
FY2027E
Trend
5Y
10Y
Peers
69.29
Revenue₹B
—
—
—
—
—
49.13
53.49
58.49
64.09
69.29
74.19
8.97%
8.97%
17
8.11
Revenue growth%
—
—
—
—
—
—
8.86
9.35
9.58
8.11
7.07
9.11
—
43
46.52
Gross margin%
—
—
—
—
—
45.70
44.17
44.73
45.23
46.52
46.47
45.23
45.23
20
26.21
Operating margin%
—
—
—
—
—
20.76
21.31
23.67
25.37
26.21
26.23
23.67
23.67
90
22.40
Net margin%
—
—
—
—
—
16.26
17.75
20.54
22.07
22.40
22.45
20.54
20.54
90
36.07
P/E ratio (avg)x
—
—
—
—
—
48.31
43.80
43.18
42.98
41.39
33.62
43.18
43.18
35
30.82
EV/EBITx
—
—
—
—
—
37.84
36.49
37.47
37.39
35.36
28.77
37.39
37.39
26
—
FCF yield (avg)%
—
—
—
—
—
—
—
—
—
—
—
—
—
50
—
FCF margin%
—
—
—
—
—
—
—
—
—
—
—
—
—
87
—
FCF / Net incomex
—
—
—
—
—
—
—
—
—
—
—
—
—
62
—
ROIC%
—
—
—
—
—
—
—
—
—
—
—
—
—
87
—
Return on equity%
—
—
—
—
—
—
—
—
—
—
—
—
—
93
—
Return on assets%
—
—
—
—
—
—
—
—
—
—
—
—
—
93
730.39
EPS₹
—
—
—
—
—
375.87
446.80
565.30
665.64
730.39
783.66
18.07%
18.07%
—
9.73
EPS growth%
—
—
—
—
—
—
18.87
26.52
17.75
9.73
7.29
18.31
—
38
—
Bookvalue per sh₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
FCF per share₹
—
—
—
—
—
—
—
—
—
—
—
—
—
—
525.00
Dividend per sh₹
—
—
—
—
—
145.00
180.00
410.00
475.00
525.00
560.07
37.94%
37.94%
—
1.99
Div yield (avg)%
—
—
—
—
—
0.80
0.92
1.68
1.66
1.74
2.13
1.66
1.66
70
71.88
Payout ratio%
—
—
—
—
—
38.58
40.29
72.53
71.36
71.88
71.47
71.36
71.36
86
21.25
Shares (diluted)M
—
—
—
—
—
21.25
21.25
21.25
21.25
21.25
◌21.25
—
—
48
—
Buyback yield%
—
—
—
—
—
—
—
—
—
—
◌—
—
—
48
—
D/E ratiox
—
—
—
—
—
—
—
—
—
—
—
—
—
79
559.8
Enterprise value₹B
—
—
—
—
—
385.9
415.8
518.7
607.9
642.3
559.8
13.59%
13.59%
53
—
LT debt₹M
—
—
—
—
—
—
—
—
—
—
—
—
—
13
Peers (US$5.968B)
Cap (US$)
PE
6.744B
29.36x
5.568B
42.33x
5.236B
35.06x
Capital
TTM
5Y
10Y
Leveragex
—
—
—
EBIT/Intx
87.78
93.11
93.11
Own earn%
—
—
—
Sh yield%
1.99
1.67
1.67
Owners
Insiders/Inst%
—
8.18
Short interest%
—
SBC / revenue%
0.20
Record
10Y
Profitable years
5/5
Revenue growth years
4/4
EPS growth years
4/4
Dividend streakyrs
3
Op margin range%
21–26
$1 testx
—
Incr. ROIC%
—

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management.

Growth vs revenue
Latest
Trend
4Y CAGR
Rel growth
Revenue
₹69.29B
8.97%
1.00×
Cost of revenue
₹37.06B
8.56%
0.98×
Operating expenses
₹14.07B
3.51%
0.81×
Revenue by region
No breakdown available
Reinvestment returns
n/m
Trend
Reinvestment rate
n/m
-
Return on capital
n/m
-
Spread over hurdle
n/m
-